|
Abstract:
|
In some settings, Bayesian statistics have played a key role in reliability and survival analyses. Examples include health care and pharmaceutical studies, where NIH and FDA have played a leadership role. However, in the physical sciences, there has been more reluctance to use Bayesian techniques particularly for reliability assessments. Explaining Bayesian analyses to senior management and other stakeholders is not always straightforward and can be an impediment to the adoption of Bayesian analyses. This panel will discuss some of the challenges faced when introducing Bayesian methods into these new communities (for example, prior distributions and MCMC) and will describe strategies that the panelists have found to be effective.
|
